Alzheimer´s Disease
Conditions
Brief summary
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
Interventions
Intravenous infusion every 2 weeks over 18 months
BIOLOGICALHuman albumin 0.25%
Intravenous infusion every 2 weeks over 18 months
Sponsors
Baxalta now part of Shire
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
* Males or females of age 50 to 89 years inclusive at the time of screening * Written informed consent obtained from either the subject or the subject's legally authorized representative prior to any study-related procedures * Written informed consent obtained from an able and competent caregiver who is willing to comply with the requirements of the protocol pertaining to him/her, including facilitating the subject's participation in the study * Diagnosis of Probable Alzheimer´s Disease (AD) according to NINCDS-ADRDA\* 1984 criteria (\* National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association) * Dementia of mild to moderate severity (Mini-Mental State Examination \[MMSE\] 16-26 inclusive at the time of screening) * Neuroimaging (computed tomography \[CT\] or MRI) performed after symptom onset consistent with AD diagnosis * Willingness to comply with the requirements of the protocol and ability to comply with testing and infusion regimen, including adequate corrected visual acuity and hearing ability * For at least 12 weeks prior to screening, on stable doses of AD medication(s) approved by local regulatory authorities. Subjects must not be on two acetylcholinesterase inhibitors concurrently. * Venous access for repeated infusion and phlebotomy * If receiving psychoactive medications (eg, antidepressants other than monoamine oxidase inhibitors \[MAOIs\] and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc.), must be on stable doses for at least 6 weeks prior to screening * For women of childbearing potential, the subject must have a negative pregnancy test at screening and must agree to employ adequate contraceptive measures (eg, birth control pills/patches, intrauterine device, or diaphragm or condom \[for male partner\] with spermicidal jelly or foam) throughout the course of the study * For subjects with a coronary artery stent, the subject must receive documented medical clearance from an interventional cardiologist stating that the subject is not at increased risk for stent occlusion with immunoglobulin treatment * For subjects with an endovascular stent, the subject must receive documented medical clearance from a vascular surgeon stating that the subject is not at increased risk for thromboembolic events with immunoglobulin treatment Main
Exclusion criteria
* Possible AD by NINCDS-ADRDA criteria or non-Alzheimer dementia (eg, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, or dementia arising from other diseases or conditions such as Parkinson's disease, vitamin B12 deficiency, thyroid abnormalities) * Current residence in a skilled nursing facility * Contraindication to undergoing MRI (eg, pacemaker \[with the exception of an MRI-compatible pacemaker\], severe claustrophobia, ferromagnetic implants such as a metal plate) * Clinically significant congestive heart failure (eg, New York Heart Association \[NYHA\] Class III/IV symptoms or untreated Class II) * Current atrial fibrillation of unstable angina (angina at rest) or history of myocardial infarction within the 12 months prior to screening * Uncontrolled hypertension defined as systolic blood pressure \> 160 mm Hg and/or diastolic \> 100 mm Hg confirmed upon repeated measures * History of thrombosis and/or thromboembolic disease (central or peripheral) within the 12 months prior to screening * Known history of procoagulant abnormalities (eg, factor V Leiden, antiphospholipid syndrome, protein S/protein C deficiency, AT III deficiency) * History of intracerebral hemorrhage within the 5 years prior to screening * Evidence on MRI of: greater than 4 microhemorrhages (regardless of their anatomical location or diagnostic characterization as possible or definite), a single area of superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, prominent white matter disease with a rating score of 3 on the age-related white matter changes (ARWMC) scale from the European Task Force on ARWMC, or multiple lacunae (defined as more than 2 lacunae that are greater than 0.5 mm in size) * Head trauma with loss of consciousness, contusion, or open head injury within the 12 months prior to screening * Uncontrolled seizure disorder as defined by two or more breakthrough seizures per year despite adequate antiepileptic drug (AED) treatment * Modified Hachinski score \> 4 at time of screening * Subjects with active malignancy or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment * Active autoimmune or neuro-immunologic disorder * Uncontrolled major depression, psychosis, or other major psychiatric disorder(s) * Poorly controlled diabetes, defined as glycosylated (or glycated) hemoglobin (HbA1c) ≥ 6.5% at screening * Creatinine clearance \< 50% of normal adjusted for age and gender, as calculated according to the Cockcroft-Gault formula, at the time of screening * Known history of untreated vitamin B12 deficiency within 6 months prior to screening, or clinically significant abnormally low vitamin B12 at the time of screening * Abnormal clinical chemistry panel or hematology panel meeting any one of the following criteria: * Serum alanine aminotransferase (ALT) \> 2.5 x upper limit of normal (ULN) * Clinically significant anemia that precludes repeated blood sampling or hemoglobin (Hgb) \< 10.0 g/dL * Absolute neutrophil count (ANC) \< 1000 cells/µL * Known coagulopathy or platelet counts \< 100,000 cells/µL * Total serum protein \> 9 g/dL * Known history of or positive serology at screening for one or more of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) type 1/2 antibody * Immunoglobulin A (IgA) deficiency (\< 8 mg/dL) * Known history of hypersensitivity following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin) * Currently receiving or has received: anti-CD20 therapy within 12 months prior to screening, or other immunomodulatory therapies (e.g. anti-TNF, anti-IL-1, interferon) within 12 weeks prior to screening. The following exceptions are allowed: non-systemic corticosteroids (eg, topical, opthalmic or inhaled glucocorticoids) and low-dose systemic corticosteroids (prednisone \< 10 mg/day or its equivalent) * Currently receiving or has received intravenous or subcutaneous immunoglobulin treatment within the 2 years prior to screening, or has received immunoglobulin in Baxter Protocol 160701 * Currently receiving or has received at any time active immunization aimed at modulating AD progression * Currently receiving or has received within 12 months prior to screening any investigational device, drug or biologic (eg passive immunotherapies with monoclonal or polyclonal antibodies) aimed at modulating AD progression * Subject has been exposed to an investigational product (IP) or investigational device within 12 weeks prior to screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study * Subject is a family member or employee of the investigator * The subject is nursing or intends to begin nursing during the course of the study * Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, urine tests, electrocardiogram, chest x-ray), that in medical judgment may impede the subject's participation in the study, pose increased risk to the subject, or confound the results of the study * Currently receiving anti-coagulant agent and/or anti-platelet agent other than acetylsalicylic acid (a.k.a. aspirin)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog) | Baseline to 9 Months (actual time frame) | The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration. |
| Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory | Baseline to 9 Months (actual time frame) | The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement | Baseline to 9 Months (actual time frame) | — |
| Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD) | Baseline to 9 Months (actual time frame) | The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life. |
| Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ) | Baseline to 9 Months (actual time frame) | The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48. |
| Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Throughout the study period: 18 Months | — |
| ADCS-Clinical Global Impression of Change (CGIC) at 18 Months | Baseline to 9 Months (actual time frame) | The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). |
| Number of Infusions Temporally Associated With AEs and/or SAEs | During or within 72 hours of completion of an infusion | A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality. |
| Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion | During or within 7 days of completion of an infusion | — |
| Number of Infusions Causally Associated With AEs and/or SAEs | Throughout the study period: 18 Months | — |
| Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE | Throughout infusions, approximately 2-5 hours | — |
| Number of Participants Experiencing Any AEs and/or SAEs | Throughout the study period: 18 Months | — |
| Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI) | Baseline to 9 Months (actual time frame) | The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment. |
Countries
Australia, Belgium, Canada, Japan, Poland, Spain, United Kingdom, United States
Participant flow
Recruitment details
Enrollment was conducted at 58 clinical sites worldwide.
Pre-assignment details
Of 508 enrolled subjects, 303 met entry criteria. 42 subjects discontinued before randomization due to study termination. Of 261 randomized subjects, 10 subjects discontinued before receiving treatment (7 study termination, 2 withdrawal by subject, 1 withdrawal by caregiver). Number of subjects who received treatment (IVIG,10% or placebo) = 251.
Participants by arm
| Arm | Count |
|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months | 83 |
| IGIV, 10% at Low Dose (0.2 g/kg) Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months | 85 |
| Placebo Control Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months | 83 |
| Total | 251 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 5 | 1 | 1 |
| Overall Study | Protocol Violation | 0 | 0 | 1 |
| Overall Study | Study termination | 73 | 87 | 79 |
| Overall Study | Use of prohibited medication | 1 | 0 | 0 |
| Overall Study | Withdrawal by Caregiver | 0 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 6 | 2 | 3 |
Baseline characteristics
| Characteristic | IGIV, 10% at High Dose (0.4 g/kg) | Total | Placebo Control | IGIV, 10% at Low Dose (0.2 g/kg) |
|---|---|---|---|---|
| Age, Continuous | 72.0 years STANDARD_DEVIATION 8.36 | 70.8 years STANDARD_DEVIATION 9.01 | 70.6 years STANDARD_DEVIATION 9.98 | 69.9 years STANDARD_DEVIATION 8.59 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 4 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 5 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 2 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 81 Participants | 238 Participants | 78 Participants | 79 Participants |
| Region of Enrollment Belgium | 6 Participants | 17 Participants | 6 Participants | 5 Participants |
| Region of Enrollment Canada | 8 Participants | 22 Participants | 7 Participants | 7 Participants |
| Region of Enrollment Japan | 0 Participants | 2 Participants | 1 Participants | 1 Participants |
| Region of Enrollment Spain | 3 Participants | 11 Participants | 3 Participants | 5 Participants |
| Region of Enrollment United States | 66 Participants | 199 Participants | 66 Participants | 67 Participants |
| Sex: Female, Male Female | 43 Participants | 132 Participants | 52 Participants | 37 Participants |
| Sex: Female, Male Male | 40 Participants | 119 Participants | 31 Participants | 48 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 30 / 83 | 33 / 85 | 30 / 83 |
| serious Total, serious adverse events | 5 / 83 | 7 / 85 | 7 / 83 |
Outcome results
Primary
Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
Time frame: Baseline to 9 Months (actual time frame)
Population: Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory | -8.1 Scores on a scale | Standard Deviation 7.36 |
| IGIV, 10% at Low Dose (0.2 g/kg) | Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory | -5.0 Scores on a scale | Standard Deviation 11.64 |
| Placebo Control | Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory | -3.8 Scores on a scale | Standard Deviation 9.26 |
p-value: 0.03395% CI: [-7.4, -0.3]Mixed Models Analysis
p-value: 0.58695% CI: [-4.2, 2.4]Mixed Models Analysis
Primary
Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
Time frame: Baseline to 9 Months (actual time frame)
Population: Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog) | 4.0 Scores on a scale | Standard Deviation 6.44 |
| IGIV, 10% at Low Dose (0.2 g/kg) | Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog) | 4.4 Scores on a scale | Standard Deviation 8.56 |
| Placebo Control | Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog) | 3.1 Scores on a scale | Standard Deviation 4.28 |
p-value: 0.24395% CI: [-1, 3.9]Mixed Models Analysis
p-value: 0.3795% CI: [-1.2, 3.3]Mixed Models Analysis
Secondary
ADCS-Clinical Global Impression of Change (CGIC) at 18 Months
The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Time frame: Baseline to 9 Months (actual time frame)
Population: Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | ADCS-Clinical Global Impression of Change (CGIC) at 18 Months | 4.3 Scores on a scale |
| IGIV, 10% at Low Dose (0.2 g/kg) | ADCS-Clinical Global Impression of Change (CGIC) at 18 Months | 4.4 Scores on a scale |
| Placebo Control | ADCS-Clinical Global Impression of Change (CGIC) at 18 Months | 4.5 Scores on a scale |
p-value: 0.50195% CI: [-1, 0.5]Mixed Models Analysis
p-value: 0.78395% CI: [-0.7, 0.5]Mixed Models Analysis
Secondary
Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)
The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.
Time frame: Baseline to 9 Months (actual time frame)
Population: Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ) | 5.8 Scores on a scale | Standard Deviation 4.13 |
| IGIV, 10% at Low Dose (0.2 g/kg) | Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ) | 1.9 Scores on a scale | Standard Deviation 6.66 |
| Placebo Control | Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ) | 1.4 Scores on a scale | Standard Deviation 5.97 |
Secondary
Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.
Time frame: Baseline to 9 Months (actual time frame)
Population: Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD) | -0.1 Scores on a scale | Standard Deviation 4.43 |
| IGIV, 10% at Low Dose (0.2 g/kg) | Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD) | 0.4 Scores on a scale | Standard Deviation 3.68 |
| Placebo Control | Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD) | 0.1 Scores on a scale | Standard Deviation 4.56 |
p-value: 0.63395% CI: [-2.8, 1.7]Mixed Models Analysis
p-value: 0.98195% CI: [-2, 2]Mixed Models Analysis
Secondary
Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)
The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.
Time frame: Baseline to 9 Months (actual time frame)
Population: Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI) | 2.3 Scores on a scale | Standard Deviation 5.76 |
| IGIV, 10% at Low Dose (0.2 g/kg) | Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI) | 3.8 Scores on a scale | Standard Deviation 12.44 |
| Placebo Control | Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI) | 0.6 Scores on a scale | Standard Deviation 5.68 |
p-value: 0.57195% CI: [-2.6, 4.7]Mixed Models Analysis
p-value: 0.03295% CI: [0.3, 7.1]Mixed Models Analysis
Secondary
Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement
Time frame: Baseline to 9 Months (actual time frame)
Population: Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement | 0.00065 mm^3 | Standard Deviation 0.00059 |
| IGIV, 10% at Low Dose (0.2 g/kg) | Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement | 0.00057 mm^3 | Standard Deviation 0.0007 |
| Placebo Control | Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement | 0.00067 mm^3 | Standard Deviation 0.00163 |
p-value: 0.59395% CI: [-0.00126, 0.00073]ANCOVA
p-value: 0.9495% CI: [-0.0008, 0.00086]ANCOVA
Secondary
Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion
Time frame: During or within 7 days of completion of an infusion
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion | 97 infusions |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion | 107 infusions |
| Placebo Control | Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion | 72 infusions |
Secondary
Number of Infusions Causally Associated With AEs and/or SAEs
Time frame: Throughout the study period: 18 Months
Population: The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Infusions Causally Associated With AEs and/or SAEs | 46 infusions |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Infusions Causally Associated With AEs and/or SAEs | 48 infusions |
| Placebo Control | Number of Infusions Causally Associated With AEs and/or SAEs | 30 infusions |
Secondary
Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE
Time frame: Throughout infusions, approximately 2-5 hours
Population: The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE | 7 infusions |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE | 2 infusions |
| Placebo Control | Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE | 1 infusions |
Secondary
Number of Infusions Temporally Associated With AEs and/or SAEs
A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.
Time frame: During or within 72 hours of completion of an infusion
Population: The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Infusions Temporally Associated With AEs and/or SAEs | 72 infusions |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Infusions Temporally Associated With AEs and/or SAEs | 80 infusions |
| Placebo Control | Number of Infusions Temporally Associated With AEs and/or SAEs | 47 infusions |
Secondary
Number of Participants Experiencing Any AEs and/or SAEs
Time frame: Throughout the study period: 18 Months
Population: The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Participants Experiencing Any AEs and/or SAEs | Participants with non-serious AEs | 55 participants |
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Participants Experiencing Any AEs and/or SAEs | Participants with AEs (incl SAEs) | 57 participants |
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Participants Experiencing Any AEs and/or SAEs | Participants with serious AEs (SAEs) | 5 participants |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Participants Experiencing Any AEs and/or SAEs | Participants with non-serious AEs | 53 participants |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Participants Experiencing Any AEs and/or SAEs | Participants with AEs (incl SAEs) | 54 participants |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Participants Experiencing Any AEs and/or SAEs | Participants with serious AEs (SAEs) | 7 participants |
| Placebo Control | Number of Participants Experiencing Any AEs and/or SAEs | Participants with AEs (incl SAEs) | 49 participants |
| Placebo Control | Number of Participants Experiencing Any AEs and/or SAEs | Participants with serious AEs (SAEs) | 7 participants |
| Placebo Control | Number of Participants Experiencing Any AEs and/or SAEs | Participants with non-serious AEs | 48 participants |
Secondary
Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
Time frame: Throughout the study period: 18 Months
Population: The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related non-serious AEs | 30 participants |
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related AEs (incl SAEs) | 31 participants |
| IGIV, 10% at High Dose (0.4 g/kg) | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related SAEs | 1 participants |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related non-serious AEs | 25 participants |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related AEs (incl SAEs) | 25 participants |
| IGIV, 10% at Low Dose (0.2 g/kg) | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related SAEs | 0 participants |
| Placebo Control | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related AEs (incl SAEs) | 16 participants |
| Placebo Control | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related SAEs | 1 participants |
| Placebo Control | Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs) | Participants with product-related non-serious AEs | 16 participants |